<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>17555117</identifier>
<setSpec>0556-6177</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>García, R</dc:author>
<dc:author>Rodríguez, P</dc:author>
<dc:author>de Gaona, E Ruiz</dc:author>
<dc:author>Páramo, J A</dc:author>
<dc:description xml:lang="en">Management of acute coronary syndromes (ACS) has moved rapidly in parallel with our understanding of the pathophysiological basis of the disease. In the eighties, the demonstration of the pivotal role of coronary thrombosis in the etiology of a ACS led to administration of aspirin and unfractionated heparin. In recent years, new medical and invasive therapies have been developed: anti-platelets (thienopyridines and glycoprotein Ilb/IlIa inhibitors), antithrombins (low molecularweight heparins) and most recently, factor Xa inhibitors (pentasaccharides). As new treatments are rapidly added, clinicians are constantly challenged to incorporate new information and guidelines into their practices in a timely fashion.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2007 Jan-Mar </dc:date>
<dc:title xml:lang="es">Antiagregación y anticoagulación en síndromes coronarios agudos: niveles de evidencia.</dc:title>
<dc:title xml:lang="en">[Antiplatelets and anticoagulants in acute coronary syndromes: levels of evidence].</dc:title>
<dc:publisher>Revista de medicina de la Universidad de Navarra</dc:publisher>
</metadata>
</record>
</pubmed-document>
